Spero Therapeutics Q1 2024 GAAP EPS $(0.24) Misses $(0.04) Estimate, Sales $9.267M Miss $21.533M Estimate
Spero Therapeutics Q1 2024 GAAP EPS $(0.24) Misses $(0.04) Estimate, Sales $9.267M Miss $21.533M Estimate
Spero Therapeutics 2024年第一季度GAAP每股收益美元（0.24）未达到预期（0.04），销售额为926.7万美元，未达到215.33万美元的预期
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.04) by 500 percent. This is a 4 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $9.267 million which missed the analyst consensus estimate of $21.533 million by 56.96 percent. This is a 347.90 percent increase over sales of $2.069 million the same period last year.
Spero Therapeutics（纳斯达克股票代码：SPRO）公布的季度亏损为每股0.24美元，比分析师普遍预期的0.04美元（0.04美元）低500％。这比去年同期每股亏损0.25美元（0.25美元）增长了4％。该公司公布的季度销售额为926.7万美元，比分析师普遍预期的215.33万美元低56.96％。这比去年同期的206.9万美元销售额增长了347.90％。